This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Luminex (LMNX) Up 13.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex (LMNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Luminex's (LMNX) Q3 earnings benefit from higher revenues and solid performance across System Sales, Consumable Sales and Service Revenues. However, gross margin contraction remains a woe.
Luminex Gets FDA Nod for ARIES MRSA Assay, Boosts Platform
by Zacks Equity Research
Luminex (LMNX) receives FDA clearance for the ARIES MRSA assay, which is likely to provide a boost to the company's ARIES platform.
Luminex (LMNX) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Higher revenues and solid performance across System Sales, Consumable Sales and Royalty Revenues benefit Luminex's (LMNX) Q2 earnings. However, gross margin contraction remains a woe.
Earnings Preview: Luminex (LMNX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Luminex (LMNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Luminex (LMNX) Presents ARIES MRSA Assay to FDA for Clearance
by Zacks Equity Research
Luminex (LMNX) submits the ARIES MRSA assay to the FDA for clearance. The company's ARIES system will get a substantial boost once the FDA clearance is through.
Why Is Luminex (LMNX) Down 3.1% Since Last Earnings Report?
by Zacks Equity Research
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex xMAP Picked by EDP Biotech to Boost Cancer Diagnostics
by Zacks Equity Research
Management at Luminex (LMNX) expects to see robust demand for Luminex's xMAP technology in 2019.
Luminex (LMNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Luminex (LMNX) Q1 results gain from higher revenues from System sales, Royalty as well as Service segments. However, contraction in gross margin remains a woe.
Luminex (LMNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Luminex (LMNX) delivered earnings and revenue surprises of -200.00% and -0.86%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?